Natalie B. Collins

5.0k total citations · 2 hit papers
21 papers, 1.7k citations indexed

About

Natalie B. Collins is a scholar working on Oncology, Molecular Biology and Immunology. According to data from OpenAlex, Natalie B. Collins has authored 21 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 6 papers in Molecular Biology and 6 papers in Immunology. Recurrent topics in Natalie B. Collins's work include Cancer Immunotherapy and Biomarkers (7 papers), CAR-T cell therapy research (4 papers) and Neuroblastoma Research and Treatments (4 papers). Natalie B. Collins is often cited by papers focused on Cancer Immunotherapy and Biomarkers (7 papers), CAR-T cell therapy research (4 papers) and Neuroblastoma Research and Treatments (4 papers). Natalie B. Collins collaborates with scholars based in United States, Canada and Australia. Natalie B. Collins's co-authors include W. Nicholas Haining, Robert T. Manguso, Vikram R. Juneja, Arlene H. Sharpe, Martin W. LaFleur, Gordon J. Freeman, Kathleen A. McGuire, Kevin Bi, Brian C. Miller and Kathleen B. Yates and has published in prestigious journals such as Nature, The Journal of Experimental Medicine and Journal of Clinical Oncology.

In The Last Decade

Natalie B. Collins

20 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target

2017 774 citations Robert T. Manguso, Hans W. Pope et al. Nature profile →
PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity

2017 612 citations Vikram R. Juneja, Kathleen A. McGuire et al. The Journal of Experimental Medicine profile →

Peers

Natalie B. Collins

ONCOL

IMMUN

PRM

Jai Rautela Australia

Robert T. Manguso United States

Eleni Maniati United Kingdom

Munehide Nakatsugawa Japan

Jesse M. Zaretsky United States

Nikolina Bąbała Netherlands

Serena S. Kwek United States

Cristina Puig-Saus United States

Flavian D. Brown United States

Rong En Tay United States

Jai Rautela Australia

Natalie B. Collins

1.0k ×1.1

ONCOL

1.3k ×1.6

IMMUN

648 ×0.8

226 ×1.2

136 ×0.8

PRM

Citations per year, relative to Natalie B. Collins Natalie B. Collins (= 1×) peers Jai Rautela

Countries citing papers authored by Natalie B. Collins

Since Specialization

Citations

This map shows the geographic impact of Natalie B. Collins's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Natalie B. Collins with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Natalie B. Collins more than expected).

Fields of papers citing papers by Natalie B. Collins

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Natalie B. Collins. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Natalie B. Collins. The network helps show where Natalie B. Collins may publish in the future.

Co-authorship network of co-authors of Natalie B. Collins

This figure shows the co-authorship network connecting the top 25 collaborators of Natalie B. Collins. A scholar is included among the top collaborators of Natalie B. Collins based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Natalie B. Collins. Natalie B. Collins is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Stutzman, Sonja E., MinJae Lee, Avanthi Tayi Shah, et al.. (2025). Feasibility of Atezolizumab in Combination With Chemotherapy for Children With Relapsed or Refractory Solid Tumors. Pediatric Blood & Cancer. 72(12). e32046–e32046.

Gikandi, Ajami, Susan Chi, Kee Kiat Yeo, et al.. (2024). Off‐label prescribing of immune checkpoint inhibitor therapy at a single pediatric cancer center. Cancer Medicine. 13(8). e7154–e7154. 3 indexed citations

Christenson, Eric S., Jeremiah A. Wala, Rose Parkinson, et al.. (2024). Abstract CT007: Phase 1/2 trial of copanlisib in combination with nivolumab for microsatellite stable (MSS) colorectal cancer (CRC). Cancer Research. 84(7_Supplement). CT007–CT007. 2 indexed citations

Collins, Natalie B., Rose Al Abosy, Brian C. Miller, et al.. (2022). PI3K activation allows immune evasion by promoting an inhibitory myeloid tumor microenvironment. Journal for ImmunoTherapy of Cancer. 10(3). e003402–e003402. 47 indexed citations

Neel, Dylan V., Clement Ma, Natalie B. Collins, et al.. (2022). Derivation and validation of a risk classification tree for patients with synovial sarcoma. Cancer Medicine. 12(1). 170–178. 2 indexed citations

Wachter, Franziska, Alyaa Al‐Ibraheemi, Maria Trissal, et al.. (2021). Molecular Characterization of Inflammatory Tumors Facilitates Initiation of Effective Therapy. PEDIATRICS. 148(6). 2 indexed citations

Forrest, Suzanne J., Cassie Kline, Thomas F. Cash, et al.. (2021). Phase II study of nivolumab and ipilimumab in children and young adults with INI1-negative cancers.. Journal of Clinical Oncology. 39(15_suppl). TPS10055–TPS10055. 4 indexed citations

Morgenstern, Daniel A., Natalie B. Collins, Rebecca Deyell, et al.. (2021). Pilot study of nivolumab in pediatric patients with hypermutant cancers.. Journal of Clinical Oncology. 39(15_suppl). 10011–10011. 3 indexed citations

Forrest, Suzanne J., Alyaa Al‐Ibraheemi, Duong Doan, et al.. (2020). Genomic and Immunologic Characterization of INI1-Deficient Pediatric Cancers. Clinical Cancer Research. 26(12). 2882–2890. 36 indexed citations

10.

Liu, Kevin X., Natalie B. Collins, Katie A. Greenzang, et al.. (2020). The use of interval‐compressed chemotherapy with the addition of vincristine, irinotecan, and temozolomide for pediatric patients with newly diagnosed desmoplastic small round cell tumor. Pediatric Blood & Cancer. 67(10). e28559–e28559. 12 indexed citations

11.

Dombrowski, Natasha D., Nikolaus E. Wolter, Caroline D. Robson, et al.. (2020). Role of Surgery in Rhabdomyosarcoma of the Head and Neck in Children. The Laryngoscope. 131(3). E984–E992. 13 indexed citations

12.

Liang, Zhuobin, Fengshan Liang, Yaqun Teng, et al.. (2019). Binding of FANCI-FANCD2 Complex to RNA and R-Loops Stimulates Robust FANCD2 Monoubiquitination. Cell Reports. 26(3). 564–572.e5. 64 indexed citations

13.

Ocwieja, Karen E., Sara O. Vargas, Scott Elisofon, et al.. (2019). Pediatric post‐transplant hepatic kaposi sarcoma due to donor‐derived human herpesvirus 8. Pediatric Transplantation. 23(3). e13384–e13384. 13 indexed citations

14.

Collins, Natalie B., Rose Al Abosy, Brian C. Miller, et al.. (2019). PI3K activated tumors evade tumor immunity by promoting an inhibitory myeloid microenvironment. The Journal of Immunology. 202(1_Supplement). 58.17–58.17. 4 indexed citations

15.

Manguso, Robert T., Hans W. Pope, Margaret D. Zimmer, et al.. (2017). In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target. Nature. 547(7664). 413–418. 774 indexed citations breakdown →

16.

Juneja, Vikram R., Kathleen A. McGuire, Robert T. Manguso, et al.. (2017). PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity. The Journal of Experimental Medicine. 214(4). 895–904. 612 indexed citations breakdown →

17.

Collins, Natalie B., Jernej Godec, Lihua Zou, et al.. (2013). Transcriptional Hallmarks Of Tumor Infiltrating Lymphocyte Responses To Melanoma. Blood. 122(21). 3491–3491. 2 indexed citations

18.

Collins, Natalie B., et al.. (2008). ATR-dependent phosphorylation of FANCA on serine 1449 after DNA damage is important for FA pathway function. Blood. 113(10). 2181–2190. 66 indexed citations

19.

Collins, Natalie B. & Gary M. Kupfer. (2005). Molecular Pathogenesis of Fanconi Anemia. International Journal of Hematology. 82(3). 176–183. 21 indexed citations

20.

Harkin, Damien G., John Bianco, & Natalie B. Collins. (2000). A novel approach to studying the migratory morphology of embryonic mesenchymal cells. Biology of the Cell. 92(7). 537–543. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact